Logo

Indiana Proteomics Consortium Changes Name to Inproteo

Jul 07, 2003

NEW YORK, July 7 - The Indiana Proteomics Consortium today announced that it has officially changed its name to Inproteo - a name chosen to emphasize the commercial goals of the effort, consortium officials said today.

 

"The new name suggests where we are and what we do," said John Hurrell, Inproteo's president, in a statement. "It also implies that we are a commercial venture - our research is meant to have an economic impact."

 

The consortium was founded in 2002 as a partnership between Indiana University, Purdue University, and Eli Lilly. Research conducted under the auspices of Inproteo will be commercialized through the creation of new companies, joint ventures, or licensing partnerships.

 

Inproteo said it has filed 19 patents within its first year.

 

Additional information on Inproteo is available here.

Breaking News
The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.